American Journal of Infection Control
June 2016 Volume 44, Issue 6, p619-738, e81-e102
http://www.ajicjournal.org/current

.
State of the Science Review
Evidence-based practices to increase hand hygiene compliance in health care facilities: An integrated review
Jun Rong Jeffrey Neo, Rana Sagha-Zadeh, Ole Vielemeyer, Ella Franklin
p691–704
Published in issue: June 01 2016
Highlights
:: Five key categories of hand hygiene intervention (HHI) emerged: (1) improving awareness with education (knowledge transfer, evaluation, mentoring and feedback), (2) facility design and planning, (3) unit-level protocols and procedures, (4) institution-wide programs, and (5) multimodal interventions.
:: Although some evidence-based HHI has been developed, sustaining hand hygiene compliance remains challenging.
:: Components like environmental psychology, behavioral economics, and financial rewards should be used to better understand and catalyze improved behavioral change in various contexts and environments to improve hand hygiene.
Abstract
Background
Hand hygiene (HH) in health care facilities is a key component to reduce pathogen transmission and nosocomial infections. However, most HH interventions (HHI) have not been sustainable.
Aims
This review aims to provide a comprehensive summary of recently published evidence-based HHI designed to improve HH compliance (HHC) that will enable health care providers to make informed choices when allocating limited resources to improve HHC and patient safety.
Methods
The Medline electronic database (using PubMed) was used to identify relevant studies. English language articles that included hand hygiene interventions and related terms combined with health care environments or related terms were included.
Results
Seventy-three studies that met the inclusion criteria were summarized. Interventions were categorized as improving awareness with education, facility design, and planning, unit-level protocols and procedures, hospital-wide programs, and multimodal interventions. Past successful HHIs may not be as effective when applied to other health care environments. HH education should be interactive and engaging. Electronic monitoring and reminders should be implemented in phases to ensure cost-effectiveness. To create hospitalwide programs that engage end users, policy makers should draw expertise from interdisciplinary fields. Before implementing the various components of multimodal interventions, health care practitioners should identify and examine HH difficulties unique to their organizations.
Conclusions
Future research should seek to achieve the following: replicate successful HHI in other health care environments, develop reliable HHC monitoring tools, understand caregiver-patient-family interactions, examine ways (eg, hospital leadership, financial support, and strategies from public health and infection prevention initiatives) to sustain HHC, and use simulated lab environments to refine study designs.

American Journal of Preventive Medicine
June 2016 Volume 50, Issue 6, p677-810, e163-e194
http://www.ajpmonline.org/current
Research Articles
Cost Effectiveness of HIV Prevention Interventions in the U.S.
Feng Lin, Paul G. Farnham, Ram K. Shrestha, Jonathan Mermin, Stephanie L. Sansom
p699–708
Published online: March 2 2016
Preview
The purpose of this study was to assess and compare the cost effectiveness of current HIV prevention interventions in the U.S. using a consistent, standardized methodology.

.

Guide to Community Preventive Services
Increasing Coverage of Appropriate Vaccinations: A Community Guide Systematic Economic Review
Verughese Jacob, Sajal K. Chattopadhyay, David P. Hopkins, Jennifer Murphy Morgan, Adesola A. Pitan, John M. Clymer, Community Preventive Services Task Force
p797–808
Published online: February 1 2016
Abstract
Context
Population-level coverage for immunization against many vaccine-preventable diseases remains below optimal rates in the U.S. The Community Preventive Services Task Force recently recommended several interventions to increase vaccination coverage based on systematic reviews of the evaluation literature. The present study provides the economic results from those reviews.
Evidence acquisition
A systematic review was conducted (search period, January 1980 through February 2012) to identify economic evaluations of 12 interventions recommended by the Task Force. Evidence was drawn from included studies; estimates were constructed for the population reach of each strategy, cost of implementation, and cost per additional vaccinated person because of the intervention. Analyses were conducted in 2014.
Evidence synthesis
Reminder systems, whether for clients or providers, were among the lowest-cost strategies to implement and the most cost effective in terms of additional people vaccinated. Strategies involving home visits and combination strategies in community settings were both costly and less cost effective. Strategies based in settings such as schools and MCOs that reached the target population achieved additional vaccinations in the middle range of cost effectiveness.
Conclusions
The interventions recommended by the Task Force differed in reach, cost, and cost effectiveness. This systematic review presents the economic information for 12 effective strategies to increase vaccination coverage that can guide implementers in their choice of interventions to fit their local needs, available resources, and budget.

American Journal of Public Health
Volume 106, Issue 6 (June 2016)
http://ajph.aphapublications.org/toc/ajph/current

.
HPV
The Feminization of HPV: Reversing Gender Biases in US Human Papillomavirus Vaccine Policy
American Journal of Public Health: June 2016, Vol. 106, No. 6: 983–984
Ellen M. Daley, Cheryl A. Vamos, Gregory D. Zimet, Zeev Rosberger, Erika L. Thompson, Laura Merrell
[No abstract]

.

PHARMACY IMMUNIZATION
Diffusion of Pharmacy-Based Influenza Vaccination Over Time in the United States
American Journal of Public Health: June 2016, Vol. 106, No. 6: 1099–1100.
Grace J. Chun, Jessica M. Sautter, Brandon J. Patterson, William F. McGhan
Abstract
Objectives. To examine pharmacy-based influenza vaccination using diffusion of innovation theory.
Methods. We used 1993 to 2013 Behavioral Risk Factor Surveillance System data to generate weighted prevalence rates of influenza vaccination, stratified by age (18–64 years vs ≥ 65 years) and state of residence. The diffusion of innovation theory adopter categories were residents of states allowing pharmacist vaccination before 1996 (“innovator/early adopters”), between 1996 and 1998 (“early majority”), between 1999 and 2004 (“late majority”), and in 2007 or later (“laggards”).
Results. For adults aged 18 to 64 years, vaccination rates were similar before the innovation (1993), diverged as the innovation reached the majority (2003), and were significantly lower for laggard states by 2013. Younger adults’ vaccination rates steadily increased from 12% to 16% in 1993 to 29% to 36% in 2013. For older adults, there was no significant difference in vaccination rates between adopter categories in any year and no advantage associated with adoption category.
Conclusions. Key features of pharmacy-based vaccination, including relative advantage and compatibility, are most relevant to younger adults; different interventions are warranted for older adults.

BMC Infectious Diseases

(Accessed 28 May 2016)

.
Research article
Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation
The endgame for polio eradication involves coordinated global cessation of oral poliovirus vaccine (OPV) with cessation of serotype 2 OPV (OPV2 cessation) implemented in late April and early May 2016…
Radboud J. Duintjer Tebbens, Lee M. Hampton and Kimberly M. Thompson
BMC Infectious Diseases 2016 16:231
Published on: 26 May 2016

.
Research article
Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme
Cervical cancer is the most common female cancer in Rwanda that, in 2011, became the first African country to implement a national vaccination programme against human papillomavirus (HPV).
Fidele Ngabo, Silvia Franceschi, Iacopo Baussano, M. Chantal Umulisa, Peter J. F. Snijders, Anne M. Uyterlinde, Fulvio Lazzarato, Vanessa Tenet, Maurice Gatera, Agnes Binagwaho and Gary M. Clifford
BMC Infectious Diseases 2016 16:225
Published on: 24 May 2016

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 28 May 2016)

.
Review
Research impact: a narrative review
Trisha Greenhalgh, James Raftery, Steve Hanney and Matthew Glover
BMC Medicine201614:78
DOI: 10.1186/s12916-016-0620-8
Abstract
Impact occurs when research generates benefits (health, economic, cultural) in addition to building the academic knowledge base. Its mechanisms are complex and reflect the multiple ways in which knowledge is generated and utilised. Much progress has been made in measuring both the outcomes of research and the processes and activities through which these are achieved, though the measurement of impact is not without its critics. We review the strengths and limitations of six established approaches (Payback, Research Impact Framework, Canadian Academy of Health Sciences, monetisation, societal impact assessment, UK Research Excellence Framework) plus recently developed and largely untested ones (including metrics and electronic databases). We conclude that (1) different approaches to impact assessment are appropriate in different circumstances; (2) the most robust and sophisticated approaches are labour-intensive and not always feasible or affordable; (3) whilst most metrics tend to capture direct and proximate impacts, more indirect and diffuse elements of the research-impact link can and should be measured; and (4) research on research impact is a rapidly developing field with new methodologies on the horizon.

Emerging Infectious Diseases
Volume 22, Number 6—June 2016
http://wwwnc.cdc.gov/eid/

.
Perspective
Perspectives on West Africa Ebola Virus Disease Outbreak, 2013–2016 PDF Version [PDF – 2.38 MB – 8 pages]
J. R. Spengler et al.
Summary
Many features of this outbreak reinforce the benefit of continued investment in global health security

Dispatches
Post-Ebola Measles Outbreak in Lola, Guinea, January–June 2015 PDF Version [PDF – 438 KB – 3 pages]
J. E. Suk et al.
Abstract
During public health crises such as the recent outbreaks of Ebola virus disease in West Africa, breakdowns in public health systems can lead to epidemics of vaccine-preventable diseases. We report here on an outbreak of measles in the prefecture of Lola, Guinea, which started in January 2015.

Dispatches
Changes in Childhood Pneumonia Hospitalizations by Race and Sex Associated with Pneumococcal Conjugate Vaccines PDF Version [PDF – 636 KB – 4 pages]
A. D. Wiese et al.
Abstract
Introduction of pneumococcal conjugate vaccines in the childhood immunization schedule was associated with decreases in all-cause pneumonia hospitalizations among black and white children in Tennessee, USA. Although racial disparities that existed before introduction of these vaccines have been substantially reduced, rates remain higher in boys than in girls among young children.

Global Public Health
Volume 11, Issue 5-6, 2016
http://www.tandfonline.com/toc/rgph20/current
Special Issue: Participatory Visual Methodologies in Global Public Health

.
Introduction
Participatory visual methodologies in global public health
pages 521-527
Claudia M. Mitchell & Marni Sommer
ABSTRACT
This Introduction serves to map out a range of participatory visual approaches, as well as critical issues related to the use of participatory visual methodologies in global health. In so doing, it offers both an overview of these innovative practices in global health and a consideration of some of the key questions that researchers might ask themselves in design and implementation.

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 28 May 2016]

.
Commentary
Outwitting dengue threat and epidemics resurgence in Asia-Pacific countries: strengthening integrated dengue surveillance, monitoring and response systems
Dengue is still a substantial vector-borne viral disease threat and burden of public health importance worldwide. This situation is complicated by dengue virus unprecedented resurgence and persistence …
Ernest Tambo, Jun-Hu Chen, Xiao-Nong Zhou and Emad I. M. Khater
Infectious Diseases of Poverty 2016 5:56
Published on: 27 May 2016

The Lancet
May 28, 2016 Volume 387 Number 10034 p2163-2262 e28
http://www.thelancet.com/journals/lancet/issue/current

.
Editorial
Eliminating FGM: what can health professionals do?
The Lancet
Summary
Female genital mutilation (FGM)—defined by WHO as “procedures that involve the partial or total removal of external genitalia or other injury to the female genital organs for non-medical reasons”—is internationally recognised as a violation of the human rights of girls and women. Worldwide, more than 200 million girls and women suffer the physical and psychological consequences of FGM. FGM is a harmful practice and can cause several immediate and long-term health consequences such as haemorrhage, post-traumatic stress disorder, painful urination, and complications in childbirth.

.

Comment
Yellow fever: the resurgence of a forgotten disease
Margaret Chan
Published Online: 23 May 2016
Summary
The possibility that a mosquito bite during pregnancy could cause severe brain damage in newborn babies has alarmed the public and astonished scientists. The Zika outbreak in the Americas shows how a disease that slumbered for six decades in Africa and Asia, never causing an outbreak, can become a global health emergency. The Ebola and Zika outbreaks have revealed gaping holes in our lines of defence: weak health infrastructures and capacities in west Africa and the demise of programmes for mosquito control in the Americas.

.

Series
France: nation and world
Achieving universal health coverage in France: policy reforms and the challenge of inequalities
Olivier Nay, Sophie Béjean, Daniel Benamouzig, Henri Bergeron, Patrick Castel, Bruno Ventelou
2236
Summary
Since 1945, the provision of health care in France has been grounded in a social conception promoting universalism and equality. The French health-care system is based on compulsory social insurance funded by social contributions, co-administered by workers’ and employers’ organisations under State control and driven by highly redistributive financial transfers. This system is described frequently as the French model. In this paper, the first in The Lancet’s Series on France, we challenge conventional wisdom about health care in France. First, we focus on policy and institutional transformations that have affected deeply the governance of health care over past decades. We argue that the health system rests on a diversity of institutions, policy mechanisms, and health actors, while its governance has been marked by the reinforcement of national regulation under the aegis of the State. Second, we suggest the redistributive mechanisms of the health insurance system are impeded by social inequalities in health, which remain major hindrances to achieving objectives of justice and solidarity associated with the conception of health care in France.

France: nation and world
State humanitarian verticalism versus universal health coverage: a century of French international health assistance revisited
Laëtitia Atlani-Duault, Jean-Pierre Dozon, Andrew Wilson, Jean-François Delfraissy, Jean-Paul Moatti
2250
Summary
The French contribution to global public health over the past two centuries has been marked by a fundamental tension between two approaches: State-provided universal free health care and what we propose to call State humanitarian verticalism. Both approaches have historical roots in French colonialism and have led to successes and failures that continue until the present day. In this paper, the second in The Lancet’s Series on France, we look at how this tension has evolved. During the French colonial period (1890s to 1950s), the Indigenous Medical Assistance structure was supposed to bring metropolitan France’s model of universal and free public health care to the colonies, and French State imperial humanitarianism crystallised in vertical programmes inspired by Louis Pasteur, while vying with early private humanitarian activism in health represented by Albert Schweitzer. From decolonisation to the end of the Cold War (1960–99), French assistance to newly independent states was affected by sans frontièrisme, Health for All, and the AIDS pandemic. Since 2000, France has had an active role in development of global health initiatives and favoured multilateral action for health assistance. Today, with adoption of the 2030 Sustainable Development Goals and the challenges of non-communicable diseases, economic inequality, and climate change, French international health assistance needs new direction. In the context of current debate over global health as a universal goal, understanding and acknowledging France’s history could help strengthen advocacy in favour of universal health coverage and contribute to advancing global equity through income redistribution, from healthy populations to people who are sick and from wealthy individuals to those who are poor.

Nature Reviews Immunology
June 2016 Vol 16 No 6
http://www.nature.com/nri/journal/v16/n6/index.html

.
Perspectives
Opinion
Harnessing the beneficial heterologous effects of vaccination
Helen S. Goodridge, S. Sohail Ahmed, Nigel Curtis, Tobias R. Kollmann, Ofer Levy, Mihai G. Netea, Andrew J. Pollard, Reinout van Crevel & Christopher B. Wilson
p392 | doi:10.1038/nri.2016.43
Abstract
Clinical evidence strongly suggests that certain live vaccines, in particular bacille Calmette–Guérin (BCG) and measles vaccines, can reduce all-cause mortality, most probably through protection against non-targeted pathogens in addition to the targeted pathogen. The underlying mechanisms are currently unknown. We discuss how heterologous lymphocyte activation and innate immune memory could promote protection beyond the intended target pathogen and consider how vaccinologists could leverage heterologous immunity to improve outcomes in vulnerable populations, in particular the very young and the elderly.

PLoS Currents: Outbreaks
http://currents.plos.org/outbreaks/
(Accessed 28 May 2016)

.
Research Article
Genetically Modified (GM) Mosquito Use to Reduce Mosquito-Transmitted Disease in the US: A Community Opinion Survey
May 25, 2016 ·
Introduction: Mosquito-borne infectious diseases such as dengue, chikungunya, and now Zika, pose a public health threat to the US, particularly Florida, the Gulf Coast states, and Hawaii. Recent autochthonous transmission of dengue and chikungunya in Florida, the recent dengue outbreak in Hawaii, and the potential for future local spread of Zika in the US, has led to the consideration of novel approaches to mosquito management. One such novel approach, the release of sterile genetically modified mosquitoes, has been proposed as a possible intervention, and a trial release of GM mosquitoes is being considered in one Florida community. However, this proposal has been controversial. The objective of this research was to increase understanding of community knowledge, attitudes, and beliefs regarding mosquito control and GM mosquitoes.
Methods: An 18-question self-administered survey was mailed to all households in the identified Key West, Florida neighborhood where a GM mosquito trial has been proposed. This survey was fielded between July 20, 2015 and November 1, 2015. The main outcome variable was opposition to the use of GM mosquitoes. Measures included demographic information and opinions on mosquitoes, mosquito control, and vector-borne diseases.
Results: A majority of survey respondents did not support use of GM mosquitoes as a mosquito control method.
Discussion: Reasons for opposition included general fears about possible harmful impacts of this intervention, specific worries about human and animal health impacts from the GM mosquitoes, and environmental concerns about potential negative effects on the ecosystem. Residents were more likely to oppose GM mosquito use if they had a low perception of the potential risks posed by diseases like dengue and chikungunya, if they were female, and if they were less concerned about the need to control mosquitoes in general. These findings suggest a need for new approaches to risk communication, including educational efforts surrounding mosquito control and reciprocal dialogue between residents and public health officials.

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 28 May 2016)

.
Editorial
Health Research and the World Humanitarian Summit—Not a Thousand Miles Apart
The PLOS Medicine Editors
| published 23 May 2016 | PLOS Medicine
http://dx.doi.org/10.1371/journal.pmed.1002027

May 23–24, 2016, marks the first World Humanitarian Summit (WHS), convened in Istanbul by United Nations Secretary-General Ban Ki-Moon following three years of preparatory consultations [1]. In an effort to resolve current humanitarian crises and avert future ones, the event aims to bring together heads of state, leaders of crisis-affected communities, representatives from industry, multilateral and nongovernment organizations, and other groups involved in humanitarian crises. Remarkably, the same dates bring a key meeting for another UN agency: the 69th World Health Assembly, through which member states govern the World Health Organization (WHO), meets May 23–28 in Geneva, more than 1,000 miles away.

Health crises are both cause and consequence of humanitarian crises. As part of the WHS consultation process, WHO has emphasized that “[t]he health and well-being of affected populations is the ultimate goal of humanitarian action” [2]. The Secretary-General’s report for the WHS, which includes the five-section Agenda for Humanity, describes the present situation in cataclysmic terms that include global threats to health:
Brutal and seemingly intractable conflicts have devastated the lives of millions of people…. More countries are slipping into fragility, marked by extreme poverty…. Violent extremism, terrorism and transnational crime are creating persistent instability. Growing economic inequality within countries and the widening gap between the rich and the poor are further marginalizing the most vulnerable people in society. Climate change continues to cause increased humanitarian stress as it exacerbates food insecurity, water scarcity, conflict, migration and other trends. Disasters are becoming more frequent and intense. Pandemics, epidemics and other global health threats continue to emerge frequently, and at worrying levels… [3]

In the context of this clear common ground, it seems ironic that a scheduling conflict effectively precludes health ministers and WHO leadership from attending both WHA and WHS. As journal editors, we are prompted to ask in turn how the core concerns of our work—medicine and health research—align with the priorities of the Agenda for Humanity.
Medical interventions appear in the Secretary-General’s report as part of Core Responsibility 2 (“uphold the norms that safeguard humanity”), in which the human rights of civilians are noted to include access to humanitarian medical services, care for the sick and wounded, and protection against attacks on hospitals and medical workers. We support this identification of medical services as crucially important. Having joined the call in 2014 for an end to deliberate attacks on medical services in conflict settings [4], we can scarcely conceive language sufficient to condemn the repeated bombing of hospitals in air-strikes that have since become widespread [5–7]. Core Responsibility 3 (“leave no one behind”) includes recognition that women and girls in crisis settings, as well as displaced people with disabilities and older people, are particularly at risk of poor access to health programs. Even in a document clearly intended to emphasize critical needs for political leadership and financing, these few mentions of health are notable for their brevity.

Limited mention of health and medicine may reflect the prominence of UN Sustainable Development Goal 3, devoted specifically to health and well-being; to expect each initiative to cover every important topic would invite loss of focus. Even so, moving from medical services to medical research, one finds the word “research” only once in the report’s 62 pages of text; the words “science” and “scientific” do not appear at all. Rather, the report emphasizes the need to collect, share, and analyze data for the purpose of assessing need, anticipating crises, and monitoring responses: “All actors should commit to consolidating available data in open and widely accessible databases, with adequate security and privacy protection…to inform joint analysis and a common picture of the most pressing risks. This common picture should be used to set ambitious targets towards implementing and financing preparedness and risk management strategies” [3].

In many crisis situations, a surveillance and monitoring approach may be more appropriate than the classic scientific approach of designing studies to test hypotheses and generate new, generalizable knowledge. At other times, the two approaches may overlap, testing the limits of the scientific method, as we cannot expect data obtained in a crisis situation to attain the methodological rigor of prospectively designed studies in controlled settings. In addition to publishing scientific studies, a journal may raise awareness of issues and thoughtful approaches to solutions. (Recent examples in this journal include essays on the role of physicians in refugee detention centers in Australia [8] and statistical approaches to making the most of limited mortality data on forced migrants, such as those in Southern Sudan and Iraq [9].) Nonetheless, we believe that a scientific approach has more to offer than may be apparent from the wording of the Secretary-General’s report. While opportunities to obtain sound data in crises may be fleeting and perilous, and opportunities to replicate conclusions uncertain, the results can still be illuminating and useful.

One of PLOS Medicine’s more frequently viewed and cited articles attributed one-third of deaths following the United States invasion of Iraq not to direct violence but to indirect causes such as failures of health, sanitation, and other systems [10]. We believe that this research, based on household survey reports, analyzed against a historical comparison group, and unlikely to be replicated directly, has substantially advanced understanding of the scope of humanitarian crises that follow war. While the results are necessarily estimates, had the investigation not been conducted using established scientific methodology, the reliability of the conclusions would be impossible to assess.

The widespread occurrence of current atrocities and the threat of future devastation demand action. We applaud the potential of WHS to align the necessary agencies and resources. Yet, the very need for such a summit suggests that, despite advances in human rights over recent decades, governments and agencies with the capacity to act still lack evidence for prioritizing and pursuing effective action. In humanitarian crises, collecting and monitoring data will be necessary but not sufficient; a sustainable impact on effects requires an understanding of causes, and responsible action requires investigation of how best to implement what is understood [11].

While science cannot by itself resolve disasters of such profound political and ethical dimensions, research can bring objectivity and innovation to understanding the causes of humanitarian crises and evaluating approaches to their prevention and resolution. We hope that discussions sparked by the Istanbul Summit will more closely integrate health objectives and clarify the role that original research should play in the global response to humanitarian crises.

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 28 May 2016)

.
Research Article
Epidemiology and Reporting Characteristics of Systematic Reviews of Biomedical Research: A Cross-Sectional Study
Matthew J. Page, Larissa Shamseer, Douglas G. Altman, Jennifer Tetzlaff, Margaret Sampson, Andrea C. Tricco, Ferrán Catalá-López, Lun Li, Emma K. Reid, Rafael Sarkis-Onofre, David Moher
| published 24 May 2016 | PLOS Medicine
http://dx.doi.org/10.1371/journal.pmed.1002028
Abstract
Background
Systematic reviews (SRs) can help decision makers interpret the deluge of published biomedical literature. However, a SR may be of limited use if the methods used to conduct the SR are flawed, and reporting of the SR is incomplete. To our knowledge, since 2004 there has been no cross-sectional study of the prevalence, focus, and completeness of reporting of SRs across different specialties. Therefore, the aim of our study was to investigate the epidemiological and reporting characteristics of a more recent cross-section of SRs.
Methods and Findings
We searched MEDLINE to identify potentially eligible SRs indexed during the month of February 2014. Citations were screened using prespecified eligibility criteria. Epidemiological and reporting characteristics of a random sample of 300 SRs were extracted by one reviewer, with a 10% sample extracted in duplicate. We compared characteristics of Cochrane versus non-Cochrane reviews, and the 2014 sample of SRs versus a 2004 sample of SRs. We identified 682 SRs, suggesting that more than 8,000 SRs are being indexed in MEDLINE annually, corresponding to a 3-fold increase over the last decade. The majority of SRs addressed a therapeutic question and were conducted by authors based in China, the UK, or the US; they included a median of 15 studies involving 2,072 participants. Meta-analysis was performed in 63% of SRs, mostly using standard pairwise methods. Study risk of bias/quality assessment was performed in 70% of SRs but was rarely incorporated into the analysis (16%). Few SRs (7%) searched sources of unpublished data, and the risk of publication bias was considered in less than half of SRs. Reporting quality was highly variable; at least a third of SRs did not report use of a SR protocol, eligibility criteria relating to publication status, years of coverage of the search, a full Boolean search logic for at least one database, methods for data extraction, methods for study risk of bias assessment, a primary outcome, an abstract conclusion that incorporated study limitations, or the funding source of the SR. Cochrane SRs, which accounted for 15% of the sample, had more complete reporting than all other types of SRs. Reporting has generally improved since 2004, but remains suboptimal for many characteristics.
Conclusions
An increasing number of SRs are being published, and many are poorly conducted and reported. Strategies are needed to help reduce this avoidable waste in research.

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 28 May 2016)

.
Research Article
Projected Impact of Dengue Vaccination in Yucatán, Mexico
Thomas J. Hladish, Carl A. B. Pearson, Dennis L. Chao, Diana Patricia Rojas, Gabriel L. Recchia, Héctor Gómez-Dantés, M. Elizabeth Halloran, Juliet R. C. Pulliam, Ira M. Longini
Research Article | published 26 May 2016 | PLOS Neglected Tropical Diseases
http://dx.doi.org/10.1371/journal.pntd.0004661

.
Old World Cutaneous Leishmaniasis and Refugee Crises in the Middle East and North Africa
Rebecca Du, Peter J. Hotez, Waleed S. Al-Salem, Alvaro Acosta-Serrano
Editorial | published 26 May 2016 | PLOS Neglected Tropical Diseases
http://dx.doi.org/10.1371/journal.pntd.0004545

.
Research Capacity Strengthening in Low and Middle Income Countries – An Evaluation of the WHO/TDR Career Development Fellowship Programme
Michael Käser, Christine Maure, Beatrice M. M. Halpaap, Mahnaz Vahedi, Sara Yamaka, Pascal Launois, Núria Casamitjana
Research Article | published 25 May 2016 | PLOS Neglected Tropical Diseases
http://dx.doi.org/10.1371/journal.pntd.0004631

PLoS One
http://www.plosone.org/
[Accessed 28 May 2016]

.
Research Article
Efficient Vaccine Distribution Based on a Hybrid Compartmental Model
Zhiwen Yu, Jiming Liu, Xiaowei Wang, Xianjun Zhu, Daxing Wang, Guoqiang Han
Research Article | published 27 May 2016 | PLOS ONE
http://dx.doi.org/10.1371/journal.pone.0155416

.

The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
Jack Stone, Natasha K. Martin, Matthew Hickman, Margaret Hellard, Nick Scott, Emma McBryde, Heidi Drummer, Peter Vickerman
Research Article | published 25 May 2016 | PLOS ONE
http://dx.doi.org/10.1371/journal.pone.0156213

PNAS – Proceedings of the National Academy of Sciences of the United States of America
http://www.pnas.org/content/early/
(Accessed 28 May 2016)

.
Physical Sciences – Environmental Sciences:
Mobile phone data highlights the role of mass gatherings in the spreading of cholera outbreaks
Flavio Finger, Tina Genolet, Lorenzo Mari, Guillaume Constantin de Magny, Noël Magloire Manga, Andrea Rinaldo, and Enrico Bertuzzo
PNAS 2016 ; published ahead of print May 23, 2016, doi:10.1073/pnas.1522305113
Significance
Big data and, in particular, mobile phone data are expected to revolutionize epidemiology, yet their full potential is still untapped. Here, we take a significant step forward by developing an epidemiological model that accounts for the spatiotemporal patterns of human mobility derived by directly tracking properly anonymized mobile phone users. Such data allow us to investigate, with an unprecedented level of detail, the effect that mass gatherings can have on the spreading of waterborne diseases like cholera. Identifying and understanding transmission hotspots opens the way to the implementation of novel disease control strategies.

Abstract
The spatiotemporal evolution of human mobility and the related fluctuations of population density are known to be key drivers of the dynamics of infectious disease outbreaks. These factors are particularly relevant in the case of mass gatherings, which may act as hotspots of disease transmission and spread. Understanding these dynamics, however, is usually limited by the lack of accurate data, especially in developing countries. Mobile phone call data provide a new, first-order source of information that allows the tracking of the evolution of mobility fluxes with high resolution in space and time. Here, we analyze a dataset of mobile phone records of ∼150,000 users in Senegal to extract human mobility fluxes and directly incorporate them into a spatially explicit, dynamic epidemiological framework. Our model, which also takes into account other drivers of disease transmission such as rainfall, is applied to the 2005 cholera outbreak in Senegal, which totaled more than 30,000 reported cases. Our findings highlight the major influence that a mass gathering, which took place during the initial phase of the outbreak, had on the course of the epidemic. Such an effect could not be explained by classic, static approaches describing human mobility. Model results also show how concentrated efforts toward disease control in a transmission hotspot could have an important effect on the large-scale progression of an outbreak.

Prehospital & Disaster Medicine
Volume 31 – Issue 03 – June 2016
https://journals.cambridge.org/action/displayIssue?jid=PDM&tab=currentissue

.
Special Reports
Research and Evaluations of the Health Aspects of Disasters, Part VIII: Risk, Risk Reduction, Risk Management, and Capacity Building
Marvin L. Birnbaum, Alessandro Loretti, Elaine K. Daily and Ann P. O’Rourke
June 2016, pp 300 – 308
DOI: http://dx.doi.org/10.1017/S1049023X16000285
Published online: 30 March 2016
Abstract
There is a cascade of risks associated with a hazard evolving into a disaster that consists of the risk that: (1) a hazard will produce an event; (2) an event will cause structural damage; (3) structural damage will create functional damages and needs; (4) needs will create an emergency (require use of the local response capacity); and (5) the needs will overwhelm the local response capacity and result in a disaster (ie, the need for outside assistance). Each step along the continuum/cascade can be characterized by its probability of occurrence and the probability of possible consequences of its occurrence, and each risk is dependent upon the preceding occurrence in the progression from a hazard to a disaster. Risk-reduction measures are interventions (actions) that can be implemented to: (1) decrease the risk that a hazard will manifest as an event; (2) decrease the amounts of structural and functional damages that will result from the event; and/or (3) increase the ability to cope with the damage and respond to the needs that result from an event. Capacity building increases the level of resilience by augmenting the absorbing and/or buffering and/or response capacities of a community-at-risk. Risks for some hazards vary by the context in which they exist and by the Societal System(s) involved.

Special Reports
Research and Evaluations of the Health Aspects of Disasters, Part IX: Risk-Reduction Framework
Marvin L. Birnbaum, Elaine K. Daily, Ann P. O’Rourke and Alessandro Loretti
DOI: http://dx.doi.org/10.1017/S1049023X16000352
Published online: 01 April 2016
Abstract
A disaster is a failure of resilience to an event. Mitigating the risks that a hazard will progress into a destructive event, or increasing the resilience of a society-at-risk, requires careful analysis, planning, and execution. The Disaster Logic Model (DLM) is used to define the value (effects, costs, and outcome(s)), impacts, and benefits of interventions directed at risk reduction. A Risk-Reduction Framework, based on the DLM, details the processes involved in hazard mitigation and/or capacity-building interventions to augment the resilience of a community or to decrease the risk that a secondary event will develop. This Framework provides the structure to systematically undertake and evaluate risk-reduction interventions. It applies to all interventions aimed at hazard mitigation and/or increasing the absorbing, buffering, or response capacities of a community-at-risk for a primary or secondary event that could result in a disaster. The Framework utilizes the structure provided by the DLM and consists of 14 steps: (1) hazards and risks identification; (2) historical perspectives and predictions; (3) selection of hazard(s) to address; (4) selection of appropriate indicators; (5) identification of current resilience standards and benchmarks; (6) assessment of the current resilience status; (7) identification of resilience needs; (8) strategic planning; (9) selection of an appropriate intervention; (10) operational planning; (11) implementation; (12) assessments of outputs; (13) synthesis; and (14) feedback. Each of these steps is a transformation process that is described in detail. Emphasis is placed on the role of Coordination and Control during planning, implementation of risk-reduction/capacity building interventions, and evaluation.

Social Science & Medicine
Volume 156, Pages 1-212 (May 2016)
http://www.sciencedirect.com/science/journal/02779536/156

.
Review articles
Where the lay and the technical meet: Using an anthropology of interfaces to explain persistent reproductive health disparities in West Africa
Review Article
Pages 175-183
Yannick Jaffré, Siri Suh
Abstract
Despite impressive global investment in reproductive health programs in West Africa, maternal mortality remains unacceptably high and obstetric care is often inadequate. Fertility is among the highest in the world, while contraceptive prevalence remains among the lowest. This paper explores the social and technical dimensions of this situation. We argue that effective reproductive health programs require analyzing the interfaces between technical programs and the social logics and behaviors of health professionals and client populations. Significant gaps between health programs’ goals and the behaviors of patients and health care professionals have been observed. While public health projects aim to manage reproduction, sexuality, fertility, and professional practices are regulated socially. Such projects may target technical practices, but access to care is greatly influenced by social norms and ethics. This paper shows how an empirical anthropology that investigates the social and technical interfaces of reproduction can contribute to improved global health.

Journal of Pediatric and Adolescent Gynecology
Available online 20 May 2016
Influence of Sources of Information and Parental Attitudes on Human Papillomavirus Vaccine Uptake among Adolescents
Natasha L. Underwood, MPH, CHES1, Lisa M. Gargano, PhD, MPH1, Samantha Jacobs, MPH2,
Katherine Seib, MSPH1, Christopher Morfaw, RN3, Dennis Murray, MD4, James M. Hughes, MD1, 2, Jessica M. Sales, PhD2
Abstract
Study Objective
The purpose of this study was to: 1) describe parental sources of information about human papillomavirus (HPV) vaccination for adolescents, 2) understand how parental sources of information about HPV vaccine are associated with adolescent HPV vaccine uptake and 3) understand if the relationship between a greater number of HPV related information sources and HPV vaccine uptake among adolescents is mediated by parental attitudes.
Design, Setting and Participants
We conducted a three-arm randomized controlled trial (RCT) conducted in middle and high schools in eastern Georgia from 2011-2013. As part of the trial, we surveyed parents during the final year to understand their sources of information about HPV vaccine for their adolescent. Data were collected from 360 parents via phone and online surveys.
Main Outcome Measures
Parents responded to a survey that asked them to identify demographic information, parental HPV attitudes, sources of information about HPV vaccination and HPV vaccine uptake.
Results
The majority of the sample was African American (74%, n=267) and 53% of parents (n=192) reported that their adolescent received at least 1 HPV vaccine dose. The top sources of information about HPV vaccine reported by parents were: a doctor or medical professional (80%, n=287) and television (64%, n=232). A mediation analysis shows sources of information about HPV vaccine are associated with parental attitudes, and parental attitudes about HPV vaccine are associated with vaccine uptake among adolescents.
Conclusions
These findings highlight the importance of HPV sources of information on parental attitudes.

Media/Policy Watch
This section is intended to alert readers to substantive news, analysis and opinion from the general media on vaccines, immunization, global; public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

.

New York Times
http://www.nytimes.com/
Accessed 28 May 2016
He Survived Ebola. Now He’s Fighting to Keep It From Spreading.
A doctor in Guinea tries to train health workers to halt the transmission of the disease — before it comes roaring back.
By JESSICA BENKO
MAY 26, 2016

Dr. Susan Desmond-Hellmann, Guide of the Gates Foundation
| 23 May 2016
On her second anniversary as chief executive of the Bill & Melinda Gates Foundation, a global colossus of philanthropy, Dr. Susan Desmond-Hellmann wrote of progress against smoking in the Philippines, polio across the world and sleeping sickness in Africa. Before joining the foundation, she led development of the cancer drugs Avastin and Herceptin at Genentech, then was chancellor of the University of California, San Francisco. We spoke for an hour at her office in Seattle. A condensed and edited version of the conversation follows.

.

Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 28 May 2016
Opinion
Jeremy Farrar: Preparing the WHO for the Next Outbreak
24 May 2016
The Ebola outbreak that started in 2013 confirmed what had long been evident: That the structure and approach of the World Health Organization were deeply flawed. The global community was sluggish in reacting to the crisis, with inadequate coordination and confused decision making. Vaccines and treatments that showed promise only came on stream toward the end of the epidemic, and even those owed much to luck…

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version:  A pdf of the current issue is available here:  Vaccines and Global Health_The Week in Review_21 May 2016

– blog edition: comprised of the approx. 35+ entries posted below on 15 May 2016.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
a program of the
– Division of Medical Ethics, NYU Medical School
– Children’s Hospital of Philadelphia Vaccine Education Center
Associate Faculty, Division of Medical Ethics, NYU School of Medicine

World Health Assembly – WHA69 – Geneva 23-28 May 2016.
.
:: Provisional agenda
:: Main Documents
:: Live webcast – WHA 69
This year for the first time many sessions of the World Health Assembly will be available by a live web cast, 18–26 May 2015.

Health and the World Humanitarian Summit
This 23-24 May, the global community will come together in Istanbul, Turkey for the first ever World Humanitarian Summit. Convened by the UN Secretary-General, the Summit aims to gather the best ideas on how to deliver humanitarian assistance more effectively and efficiently, to achieve real impact in the lives of people affected by crises.
:: Visit the World Humanitarian Summit website
:: Read the report of the UN Secretary-General for the World Humanitarian Summit

Zika virus [to 21 May 2016]
Public Health Emergency of International Concern (PHEIC)
http://www.who.int/emergencies/zika-virus/en/

.

WHO confirms Zika virus strain imported from the Americas to Cabo Verde
News Release
20 MAY 2016 | BRAZZAVILLE – Sequencing of the virus in Cabo Verde by Institut Pasteur, Dakar confirms that the Zika virus currently circulating in Cabo Verde is the same as the one circulating in the Americas – the Asian type- and was most likely imported from Brazil. This is the first time that the Zika strain responsible for the outbreaks linked to neurological disorders and microcephaly has been detected in Africa.

“The findings are of concern because it is further proof that the outbreak is spreading beyond South America and is on the doorstep of Africa. This information will help African countries to re-evaluate their level of risk and adapt and increase their levels of preparedness,” said Dr Matshidiso Moeti, WHO Regional Director for Africa.

As a first step, these countries should heighten risk communication to pregnant women to raise awareness of complications associated with the Asian type of Zika virus and promote protection steps to avoid mosquito bites as well as sexual transmission. In addition, countries should increase their surveillance for Zika transmission and congenital malformations, such as microcephaly, as well as Guillain-Barré syndrome.

Activated since February 2016, WHO Zika Virus Disease Incident Management System in Brazzaville and at Headquarters will continue to review existing risk assessments, increase surveillance, and assess laboratory testing capacity and support community engagement and risk communications in priority countries. In addition, WHO and its partners will support the countries in the African region to step up preparedness efforts for early detection, confirmation and management of potential complications related to Zika infection. The response will build on investments in strengthened systems made in West Africa during the Ebola emergency.

Zika in Cabo Verde
As of 8 May 2016, there have been 7557 suspected cases of Zika in Cabo Verde. Three cases of microcephaly have been reported from Cabo Verde with one case reported by the U.S. Centers for Disease Control and Prevention (CDC) after being delivered in the United States. So far, no case of Guillain-Barre Syndrome (GBS) has been reported from Cabo Verde.

WHO – Press Conference: Update on Zika Virus in Cabo Verde (Geneva, 20 May 2016)
[Video: 37:06]
20 May 2016 – WHO update on Zika virus in Cabo Verde. The speakers will present the latest development on Zika virus in Cabo Verde

.

WHO calls on countries to prepare as Zika virus expected to spread in Europe
18 May 2016
A new WHO report assesses the risk of a Zika virus disease outbreak occurring during late spring and summer in the European Region. While the overall risk is low to moderate, countries where Aedes mosquitoes are present are more likely to experience a Zika virus outbreak.

The report contains a series of actions that WHO recommends for countries, according to their likelihood of Zika transmission. WHO urges European countries, especially those with high and moderate likelihood of local Zika virus transmission, to follow these recommendations to prevent or rapidly contain a Zika virus disease outbreak.

WHO’s support to European countries to prepare for and respond to health risks such as Zika virus disease is a key aspect of the reform of WHO’s work in emergencies.

.

Zika situation report – 19 May 2016
Zika virus, Microcephaly and Guillain-Barré syndrome
Read the full situation report
Summary
:: As of 18 May 2016, 60 countries and territories report continuing mosquito-borne transmission of which:
…46 countries are experiencing a first outbreak of Zika virus since 2015, with no previous evidence of circulation, and with ongoing transmission by mosquitoes.
…14 countries reported evidence of Zika virus transmission between 2007 and 2014, with ongoing transmission.
…In addition, four countries or territories have reported evidence of Zika virus transmission between 2007 and 2014, without ongoing transmission: Cook Islands, French Polynesia, ISLA DE PASCUA – Chile and YAP (Federated States of Micronesia).

Person-to-person transmission:
:: Ten countries have reported evidence of person-to-person transmission of Zika virus, probably via a sexual route.
:: In the week to 18 May 2016, Argentina is the latest country to report mosquito-borne Zika virus transmission.
:: Microcephaly, and other fetal malformations potentially associated with Zika virus infection or suggestive of congenital infection, have been reported in eight countries or territories. Puerto Rico is the latest territory to report a case of microcephaly associated with Zika virus.
:: Two cases of microcephaly and other neurological abnormalities are currently under verification in Spain and Venezuela (Bolivarian Republic of)
:: In the context of Zika virus circulation, 13 countries and territories worldwide have reported an increased incidence of Guillain-Barré syndrome (GBS) and/or laboratory confirmation of a Zika virus infection among GBS cases. One GBS case associated with Zika virus infection in a returning traveller to the Netherlands has been reported.
:: Based on research to date, there is scientific consensus that Zika virus is a cause of
:: The global prevention and control strategy launched by the World Health Organization (WHO) as a Strategic Response Framework encompasses surveillance, response activities and research. Key interventions are being undertaken jointly by WHO and international, regional and national partners in response to this public health emergency. A draft of the Strategic Response Framework for the second half of 2016 will be shared with partners mid-May and finalized by mid-June.
:: WHO has developed new advice and information on diverse topics in the context of Zika virus. WHO’s latest information materials, news and resources to support corporate and programmatic risk communication, and community engagement are available online.

.

Zika Open [to 21 May 2016]
[Bulletin of the World Health Organization]
:: All papers available here
No new papers posted

.

CDC/ACIP [to 21 May 2016]
http://www.cdc.gov/media/index.html
FRIDAY, MAY 20, 2016
Transcript for CDC Telebriefing: Zika Virus Update – 5-20-2016
DR. DENISE JAMIESON: Good morning. As of today, national reporting of the number of U.S. pregnant women affected by Zika virus will change. Previously CDC reported the number of pregnant women with Zika virus which included only pregnant women with symptoms or pregnancy complications consistent with Zika. CDC will now report pregnancy data from two enhanced surveillance systems (The U.S. Zika Pregnancy Registry and the Puerto Rico Active surveillance system. Both of these systems include pregnant women with any laboratory evidence of possible Zika virus infection with or without symptoms. The new reporting systems are the topic of a MMWR, which has just been released. And we also be shortly updating the pregnancy numbers on the CDC’s website. I’ll now turn it over to Dr. Margaret Honein for additional comments….

FRIDAY, MAY 20, 2016
CDC Changes Reporting of Numbers of Pregnant Women affected by Zika Virus

EBOLA/EVD [to 21 May 2016]
“Threat to international peace and security” (UN Security Council)

Editor’s Note:
It appears that weekly Ebola Situation Reports have resumed. We will present the first page summary and risk assessment here.

.
EBOLA VIRUS DISEASE – SITUATION REPORT 19 MAY 2016
:: The Public Health Emergency of International Concern (PHEIC) related to Ebola in West Africa was lifted on 29 March 2016. A total of 28,616 confirmed, probable and suspected cases have been reported in Guinea, Liberia and Sierra Leone, with 11,310 deaths.

:: In the latest cluster, seven confirmed and three probable cases of Ebola virus disease (EVD) were reported between 17 March and 6 April from the prefectures of N’Zerekore (nine cases) and Macenta (one case) in south-eastern Guinea. In addition, having travelled to Monrovia, Liberia, the wife and two children of the Macenta case were confirmed as Ebola cases between 1 and 5 April.

:: The index case of this cluster (a 37-year-old female from Koropara sub-prefecture in N’Zerekore) had symptom onset on or around 15 February and died on 27 February without a confirmed diagnosis. The source of her infection is likely to have been due to exposure to infected body fluid from an Ebola survivor.

:: In Guinea, the last case tested negative for Ebola virus for the second time on 19 April. In Liberia, the last case tested negative for the second time on 28 April.

:: The 42-day (two incubation periods) countdown must elapse before the outbreak can be declared over in Guinea and Liberia. In Guinea, this is due to end on 31 May and in Liberia, this is due to end on 9 June.

:: Having contained the last Ebola virus outbreak in March 2016, Sierra Leone has maintained heightened surveillance with mandatory swabbing, testing of all reported deaths and prompt investigation and testing of all suspected cases. The swabbing policy will be reviewed on the 30 June.

Risk assessment:
For the outbreak to be declared over, a 42-day countdown must pass after the last case tested negative for Ebola virus for the second time. This countdown is due to elapse on 31 May in Guinea and on 9 June in Liberia. Until then, active surveillance in Guinea and Liberia will continue. The performance indicators suggest that Guinea, Liberia and Sierra Leone still have variable capacity to prevent, detect (epidemiological and laboratory surveillance) and respond to new outbreaks (Table 1). The risk of additional outbreaks originating from exposure to infected survivor body fluids remains and requires sustained mitigation through counselling on safe sex practices and testing of body fluids.

.

IOM Supports Guinea in Implementing Community Event-Based Surveillance System to Prevent Resurgence of Ebola
05/20/16
Guinea – IOM, in partnership with International Medical Corps (IMC), last week (14/05) officially launched the Community Event-Based Surveillance (CEBS) system in the Kindia Prefecture, in the south-western region of Guinea, along the border with Sierra Leone. This brings to a total of four, the number of prefectures in which IOM is currently implementing the CEBS activities, after the Boke, Forecariah and Dubreka Prefectures.

POLIO [to 21 May 2016]
Public Health Emergency of International Concern (PHEIC)

.
Polio this week as of 18 May 2016
:: From the 17 April to 1 May, 155 countries and territories participated in the historic trivalent to bivalent oral polio vaccine switch, withdrawing the type two component of the vaccine to protect future generations against circulating vaccine derived polioviruses. Track the switch live.

:: Preparing for the WHA: next week, health ministers from around the world will convene in Geneva for the annual World Health Assembly (WHA). Among other public health topics, delegates will review and discuss the latest global polio epidemiology. The GPEI has set up a WHA-specific polio website, with key documents to help guide discussions.

The Trivalent to Bivalent Oral Polio Vaccine Switch
:: Between 17 April and 1 May, the type 2 component of the oral polio vaccine (OPV) is being removed from use through a globally synchronized switch from the trivalent to bivalent oral polio vaccine. This is the first stage of objective 2 of the Polio Eradication and Endgame Strategic Plan 2013-2018 to withdraw OPV in a phased manner starting with the type 2 component following the eradication of wild poliovirus type 2 in September 2015.

:: Thanks to the efforts of a wide range of stakeholders from Ministries of Health, health workers, volunteers, switch monitors, WHO, UNCEF and partners of the World Health Organization, confirmation has been received that 152 countries have completed the switch.

:: Follow a live update of which countries have undergone the switch. Learn more about why the switch is such an important part of ensuring a polio-free world through this series of videos.

:: The following indicators are being carefully tracked to ensure the switch goes smoothly. As of 10 May:
…155 of 155 (100%) countries and territories have stopped using the trivalent oral polio vaccine.
…Independent monitoring to ensure the switch goes smoothly has begun in 151 countries (99%).
…The National Validation Committee has received switch monitoring data from 124 countries.
…The WHO Regional Office has received the National Validation Report from 124 countries.

Selected Country Levels Updates [excerpted]
Afghanistan
:: One new case of wild poliovirus type 1 (WPV1) was reported in the past week in Shahwalikot district of Kandahar, with onset of paralysis on 4 April. The total number of WPV1 cases for 2016 is now five, compared to one reported by this date in 2015.
Pakistan
:: One new case of wild poliovirus type 1 (WPV1) was reported in the past week, from Bannu district in Khyber Pakhtunkhwa (KP) province with onset of paralysis on 23 April. It is the most recent case in the country, and brings the total number of WPV1 cases for 2016 to ten.

.

National polio immunization campaign aims to vaccinate over 9 million children in Afghanistan
Kabul 16 May 2016 – The Ministry of Public Health, with the support of WHO and UNICEF, launched a national campaign today to vaccinate every child under the age of 5 against polio in Afghanistan. The immunization campaign will run throughout Afghanistan for 4 days with 65,000 trained health workers aiming to vaccinate over 9 million children.

During this polio immunization round all children aged 2–5 years will also receive de-worming tablets. These tablets prevent worm infections that cause anaemia, malnourishment and impaired mental and physical development in children, and improve children’s overall health and development…

Yellow Fever [to 21 May 2016]
http://www.who.int/emergencies/yellow-fever/en/

.

Meeting of the Emergency Committee under the International Health Regulations (2005) concerning Yellow Fever
WHO statement [Editor’s text bolding]
19 May 2016
An Emergency Committee (EC) regarding yellow fever was convened by the Director-General under the International Health Regulations (2005) (IHR 2005) by teleconference on 19 May 2016, from 13:00 to 17:15 Central European Time1.

The following affected States Parties participated in the information session of the meeting: Angola and the Democratic Republic of Congo.

The WHO Secretariat briefed the Committee on the history and impact of the Yellow Fever Initiative, the urban outbreak of yellow fever in Luanda, Angola and its national and international spread to the Democratic Republic of Congo, China and Kenya. The Committee was provided with additional information on the evolving risk of urban yellow fever in Africa and the status of the global stockpile of yellow fever vaccine.

After discussion and deliberation on the information provided, it was the decision of the Committee that the urban yellow fever outbreaks in Angola and the Democratic Republic of the Congo is a serious public health event which warrants intensified national action and enhanced international support. The Committee decided that based on the information provided the event does not at this time constitute a Public Health Emergency of International Concern (PHEIC).

While not considering the event currently to constitute a PHEIC, Members of the Committee strongly emphasized the serious national and international risks posed by urban yellow fever outbreaks and offered technical advice on immediate actions for the consideration of WHO and Member States in the following areas:
:: the acceleration of surveillance, mass vaccination, risk communications, community mobilization, vector control and case management measures in Angola and the Democratic Republic of Congo;

:: the assurance of yellow fever vaccination of all travellers, and especially migrant workers, to and from Angola and Democratic Republic of Congo;

:: the intensification of surveillance and preparedness activities, including verification of yellow fever vaccination in travellers and risk communications, in at-risk countries and countries having land borders with the affected countries.

The Committee also emphasized the need to manage rapidly any new yellow fever importations, thoroughly evaluate ongoing response activities, and quickly expand yellow fever diagnostic and confirmatory capacity. Recognizing the limited international supply of yellow fever vaccines, the Committee also advised the immediate application of the policy of 1 lifetime dose of yellow fever vaccine2 and the rapid evaluation of yellow fever vaccine dose-sparing strategies by the WHO Strategic Advisory Group of Experts on Immunization (SAGE).
Going forward, the Committee agreed with the planned review and revision of the global strategy for preventing urban yellow fever outbreaks in keeping with WHO’s assessment that the risk of such events is increasing.

Based on these views and the currently available information, the Director-General accepted the Committee’s assessment that the current yellow fever situation is serious and of great concern and requires intensified control measures, but does not constitute a PHEIC at this time.
The Director-General urges Member States to enforce the yellow fever vaccination requirement for travellers to and from Angola and the Democratic Republic of the Congo in accordance with the IHR (2005)3

The Director-General thanked the Committee for its thorough advice on priority actions for affected and at-risk countries, and on further yellow fever risk management work for WHO. The Director-General appreciated the concurrence of the Committee to be reconvened if needed.

.

Yellow Fever – Situation Report – 20 May 2016
Full Report:
http://apps.who.int/iris/bitstream/10665/206548/1/yellowfeversitrep_20May2016_eng.pdf?ua=1
Summary:
Three countries have reported confirmed yellow fever cases imported from Angola: Democratic Republic of The Congo (DRC) (39 cases), Kenya (two cases) and People’s Republic of China (11 cases). This highlights the risk of international spread through non-immunised travellers.

Angola: 2420 suspected cases
As of 19 May 2016, Angola has reported 2420 suspected cases of yellow fever with 298 deaths. Among those cases, 736 have been laboratory confirmed. Despite vaccination campaigns in Luanda, Huambo and Benguela provinces circulation of the virus in some districts persists.

Democratic Republic of The Congo: 44 laboratory confirmed cases
On 22 March 2016, the Ministry of Health of DRC confirmed cases of yellow fever in connection with Angola. The government officially declared the yellow fever outbreak on 23 April. As of 19 May, DRC has reported five probable cases and 44 laboratory confirmed cases: 42 imported from Angola, reported in Kongo central province and Kinshasa and two autochthonous cases in Ndjili, Kinshasa and in Matadi, Kongo Central province. The possibility of locally acquired infections is under investigation for at least eight nonclassified cases in both Kinshasa and Kongo central provinces.

Uganda: 60 suspect cases
In Uganda, the Ministry of Health notified yellow fever cases in Masaka district on 9 April 2016. As of 19 May, 60 suspect cases, of which seven are laboratory confirmed, have been reported from three districts: Masaka, Rukungiri and Kalangala. According to sequencing results, those clusters are not epidemiologically linked to Angola.

The risk of spread
The virus in Angola and DRC is largely concentrated in main cities. The risk of spread and local transmission to other provinces in the three countries remains a serious concern. The risk is high also for potential spread to bordering countries especially those classified as low risks for yellow fever disease (i.e. Namibia, Zambia) where the population, travellers and foreign workers are not vaccinated against yellow fever.

Risk assessment
The outbreak in Angola remains of high concern due to:
:: Persistent local transmission in Luanda despite the fact that more than seven million people have been vaccinated.
:: Local transmission reported in seven highly populated provinces including Luanda.
:: The continued extension of the outbreak to new provinces and new districts.
:: High risk of spread to neighbouring countries. Confirmed cases have already travelled from Angola to DRC, Kenya and People’s Republic of China. As the borders are porous with substantial crossborder social and economic activities, further transmission cannot be excluded. Viraemic patients travelling pose a risk for the establishment of local transmission especially in countries where adequate vectors and susceptible human populations are present.
:: Inadequate surveillance system capable of identifying new foci or areas of cases emerging.
:: High index of suspicion of ongoing transmission in areas hard to reach like Cabinda.

.

IFRC [to 21 May 2016]
http://www.ifrc.org/en/news-and-media/press-releases/
19 May 2016 –
Yellow fever: urgent action needed to prevent international crisis

Geneva, 19 May 2016: Fears are growing that a deadly yellow fever outbreak in Angola – which has already spread to Democratic Republic of the Congo, Kenya and China – will continue to spread internationally without immediate action to prevent it, the International Federation of Red Cross and Red Crescent Societies (IFRC) warned today.

The disease is transmitted by the Aedes aegypti mosquito, which is also responsible for spreading the Zika virus, dengue and chikungunya.

Dr Julie Lyn Hall, the IFRC’s Director of Health, said that limited vaccine supplies, inadequate disease surveillance systems, poor sanitation and everyday cross-border economic and social interaction could turn a national outbreak into a global crisis, if no immediate community-based action is taken.

“Unvaccinated travellers could transform this outbreak into a regional or international crisis if we don’t move quickly to protect vulnerable populations and help communities to reduce their risk of infection,” she said.

Yellow fever has killed 293 people in Angola since the beginning of the outbreak in December 2015, and a further 2,267 people are believed to have been infected. The IFRC released 50,672 Swiss francs from its Disaster Relief Emergency Fund (DREF) on 24 February to support Angolan Red Cross work to support the vaccination of 90,000 people, and conducting community mobilization activities with 60,000 others. A further DREF allocation in support of the Red Cross of the Democratic Republic of the Congo will be issued today…

WHO & Regional Offices [to 21 May 2016]

South–East Asia region eliminates maternal and neonatal tetanus
May 2016 — In a major public health feat, WHO South-East Asia Region has eliminated maternal and neonatal tetanus, with all districts across the 11 countries having reduced the cases to less 1 than per 1000 live births

.

Weekly Epidemiological Record (WER) 20 May 2016, vol. 91, 20 (pp. 257–264)
Contents:
257 Smallpox in the post eradication era

.

WHO-UNICEF joint statement on the comprehensive effective vaccine management (EVM) framework pdf, 960kb
19 May 2016 :: 5 pages
The World Health Organization (WHO) and the United Nations Children’s Fund (UNICEF) are intensifying and coordinating efforts to catalyse immunization supply chain improvements and performance in countries through the comprehensive EVM framework – a four-step strategy for continuous immunization supply chain improvement, quality management, optimization and innovation.

The comprehensive EVM framework builds on the success of the EVM initiative launched in 2010 to help countries evaluate the performance of their immunization supply chains, and benchmark this performance against best-practice standards.
In five years, the EVM initiative has helped to uncover important shortcomings in the performance of many countries’ immunization supply chains. Addressing these has required a comprehensive rethink of how WHO and UNICEF, together with the global immunization community, can more effectively catalyse immunization supply chain improvements in countries.

To that end, this joint statement:
1. Reiterates the vital role of immunization supply chains in achieving vaccination coverage and equity targets set by the GVAP;
2. Summarizes the evidence indicating that vaccines are not always available when needed; that weak cold chain systems are putting vaccines at risk and delaying new vaccine introduction; and that vaccines are wasted as a result of poor supply chain management;
3. Describes the comprehensive EVM framework and how WHO and UNICEF will work together to promote its use to achieve health and immunization outcomes in countries.

.

Call for 3 proposals: work related to human papillomavirus (HPV) immunization
Deadline for application: 5 June 2016
16 May 2016
The Initiative for Vaccine Research (IVR) requests the following three proposals for work related to human papillomavirus (HPV) immunization:
:: Systematic review and meta-analysis of the worldwide burden of anogenital warts
pdf, 318kb
:: Systematic review and meta-analysis of clinical trials of licensed HPV vaccines
pdf, 240kb
:: Systematic review and meta-analysis of the population-level impact and herd effects following HPV immunization programmes
pdf, 240kb
The specific objectives and deliverables of each request are accessible via the respective hyperlinks. If interested, please follow the submission instructions reported in each request.
Proposals need to be submitted by email to vicarian@who.int by 5 June 2016.

.

Disease Outbreak News (DONs)
:: 19 May 2016 – Haemorrhagic fever syndrome – South Sudan
:: 18 May 2016 – Lassa Fever – Liberia
:: 17 May 2016 – Human infection with avian influenza A(H7N9) virus – China
:: 16 May 2016 – Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia
:: 16 May 2016 – Middle East respiratory syndrome coronavirus (MERS-CoV) – Qatar

.

:: WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: WHO confirms Zika virus strain imported from the Americas to Cabo Verde
BRAZZAVILLE / 20 May 2016

WHO Region of the Americas PAHO
:: Zika risk communication, community engagement focus of new prevention efforts by CDC, CDC Foundation, PAHO in U.S. Territories and the Americas (05/18/2016)
:: More government action needed to reverse the smoking epidemic in the Americas (05/18/2016)

WHO South-East Asia Region SEARO
:: WHO South–East Asia Region eliminates Maternal and Neonatal Tetanus
19 May 2016

WHO European Region EURO
:: Women Deliver Conference – European Region challenged as best place for women and girls 20-05-2016
:: European Region successfully withdraws trivalent oral poliomyelitis (polio) vaccine 18-05-2016
:: WHO strategy highlights challenges and way forward for women’s health 18-05-2016
:: WHO calls on countries to prepare as Zika virus expected to spread in Europe in late spring and summer 18-05-2016

WHO Eastern Mediterranean Region EMRO
:: New WHO guidelines to improve care for millions living with female genital mutilation
17 May 2016
:: National polio immunization campaign aims to vaccinate over 9 million children in Afghanistan
16 May 2016

WHO Western Pacific Region
No new content identified.

CDC/ACIP [to 21 May 2016]
http://www.cdc.gov/media/index.html

.
FRIDAY, MAY 20, 2016
Transcript for CDC Telebriefing: Zika Virus Update – 5-20-2016
DR. DENISE JAMIESON: Good morning. As of today, national reporting of the number of U.S. pregnant women affected by Zika virus will change. Previously CDC reported the number of pregnant women with Zika virus which included only pregnant women with symptoms or pregnancy complications consistent with Zika. CDC will now report pregnancy data from two enhanced surveillance systems (The U.S. Zika Pregnancy Registry and the Puerto Rico Active surveillance system. Both of these systems include pregnant women with any laboratory evidence of possible Zika virus infection with or without symptoms. The new reporting systems are the topic of a MMWR, which has just been released. And we also be shortly updating the pregnancy numbers on the CDC’s website. I’ll now turn it over to Dr. Margaret Honein for additional comments….

FRIDAY, MAY 20, 2016
CDC Changes Reporting of Numbers of Pregnant Women affected by Zika Virus

.

MMWR May 20, 2016 / Vol. 65 / No. 19
:: Binational Dengue Outbreak Along the United States–Mexico Border — Yuma County, Arizona, and Sonora, Mexico, 2014

NIH [to 21 May 2016]
http://www.nih.gov/news-events/news-releases

.
May 18, 2016
Large-scale HIV vaccine trial to launch in South Africa
— NIH-funded study will test safety, efficacy of vaccine regimen.
An early-stage HIV vaccine clinical trial in South Africa has determined that an investigational vaccine regimen is safe and generates comparable immune responses to those reported in a landmark 2009 study showing that a vaccine can protect people from HIV infection.

onsequently, the National Institute of Allergy and Infectious Diseases (NIAID) and its partners have decided to advance the experimental HIV vaccine regimen into a large clinical trial. This new study, called HVTN 702, is designed to determine whether the regimen is safe, tolerable and effective at preventing HIV infection among South African adults. The trial is slated to begin in November 2016, pending regulatory approval.

“For the first time in seven years, the scientific community is embarking on a large-scale clinical trial of an HIV vaccine, the product of years of study and experimentation,” said Anthony S. Fauci, M.D., director of NIAID, part of the National Institutes of Health and a co-funder of the trial. “A safe and effective HIV vaccine could help bring about a durable end to the HIV/AIDS pandemic and is particularly needed in southern Africa, where HIV is more pervasive than anywhere else in the world.”

The experimental vaccine regimen that will be studied in HVTN 702 is now being tested in the smaller initial trial, named HVTN 100, and is based on the regimen investigated in the U.S. Military HIV Research Program-led RV144 clinical trial in Thailand that delivered landmark results in 2009. The current regimen is designed to provide greater protection than the RV144 regimen and has been adapted to the HIV subtype that predominates in southern Africa…

.

 NIH statement on HIV Vaccine Awareness Day
May 18, 2016 — Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases.
[Excerpt]
… In this regard, today NIAID is pleased to announce the decision to move forward with HVTN 702, a new Phase 2b/3 HIV vaccine efficacy clinical trial in South Africa. The study will test an investigational HIV vaccine regimen designed to improve upon the efficacy observed in the RV144 trial in Thailand and to evaluate the vaccine in a higher risk population. RV144 is the only clinical trial to demonstrate that a vaccine can protect people from HIV infection, albeit to a modest degree.

The decision to proceed with HVTN 702 was informed by early data from the HVTN 100 phase 1/2 clinical trial, which has shown that the new vaccine regimen is safe and produces a robust immune response. HVTN 100 was led by the Pox-Protein Public-Private Partnership (P5), a diverse group of organizations including NIAID committed to building on the success of the RV144 HIV vaccine trial.

Vaccine research also continues in the laboratory, where scientists are investigating the use of potent antibodies that block a high percentage of global HIV strains from infecting human cells. These so-called broadly neutralizing antibodies (bNAbs) can occur naturally; however, they occur in high titers in a relatively small proportion of infected individuals and they usually develop only after two or more years of infection, too late to be of significant benefit to the patient. However, if a vaccine could stimulate uninfected people’s immune systems to make bNAbs, the antibodies might protect those people from HIV infection.

Researchers are identifying and engineering numerous and more powerful types of bNAbs and testing them in clinical trials of passive infusion to see if they can protect uninfected people from acquiring HIV, and in HIV-infected people to see if they help keep the virus in check. Testing the ability of bNAbs in these settings will help demonstrate whether a vaccine that elicits similar antibodies or sets of antibodies can prevent HIV infection.

… HIV vaccine development has been challenging; however, the goal of developing a safe and effective vaccine that helps bring about a durable end to the HIV/AIDS pandemic is an overarching research priority. On this HIV Vaccine Awareness Day, we recognize and thank the thousands of HIV vaccine clinical trial volunteers, researchers, health professionals, advocates, and others who work in pursuit of that goal.

UNAIDS [to 21 May 2016]
http://www.unaids.org/en/resources/presscentre/

.
18 May 2016
UNAIDS calls for sustained investment and increased collaboration to develop an HIV vaccine
GENEVA —On HIV Vaccine Awareness Day, UNAIDS calls for greater resources and increased collaboration among governments, the scientific community and the private sector to advance research towards finding an effective HIV vaccine.

“Developing an effective HIV vaccine would be a major scientific and medical breakthrough for humankind,” said UNAIDS Executive Director Michel Sidibé. “Alongside expanding access to existing antiretroviral medicines and combination HIV prevention tools, sustained investment and intensified collaboration to develop an HIV vaccine is needed to bring the world a step closer to ending the AIDS epidemic.”

In 2014, global investment in HIV vaccine research and development increased by 2.8%, to US$ 841 million, up from US$ 818 million in 2013. However, this rebound followed five years during which available resources either flatlined or declined, with a high of US$ 961 million in 2007. The United States of America remains the largest investor in HIV research and development.

Public–private and international partnerships have been formed to accelerate progress towards an effective HIV vaccine. UNAIDS is working together with partners, such as the International AIDS Vaccine Initiative, AVAC and other stakeholders, to advance research. UNAIDS is also an active participant in the annual vaccine funders’ meetings coordinated by the Global HIV Vaccine Enterprise to highlight the importance of continued research, sustained funding and coordinated responses towards HIV vaccine discovery.

Over the past 30 years, four concepts for an HIV vaccine have been tested in six efficacy trials. Of these, the RV144 vaccine trial in Thailand in 2009 was most promising, reducing HIV infection risk by 31%. It is hoped that ongoing research will lead to at least two further large-scale trials of vaccine candidates starting in the near future. At the same time, work continues to develop other potential vaccines, including a combined vaccine for HIV and hepatitis C. The effectiveness of neutralizing antibodies is also being studied.

An HIV vaccine will be necessary for the long-term control of HIV and is the best hope for sustaining the progress made towards ending the AIDS epidemic by 2030.

IAVI [International Aids Vaccine Initiative] [to 21 May 2016]
http://www.iavi.org/press-releases/2016

.
May 19, 2016
New HIV-Mimicking Particles That Trigger Immune Response Could Advance AIDS Vaccine Design

.
May 17, 2016
Insights into the Development of Antibodies That Target a Large Portion of HIV Strains Could Advance Vaccine Design

World Bank Group Launches Groundbreaking Financing Facility to Protect Poorest Countries against Pandemics
May 21, 2016 – PRESS RELEASE
First-ever insurance and pandemic bonds will save lives and protect economies

SENDAI, Japan, May 21, 2016—The World Bank Group today launched the Pandemic Emergency Financing Facility (PEF), an innovative, fast-disbursing global financing mechanism designed to protect the world against deadly pandemics, which will create the first-ever insurance market for pandemic risk. Japan, which holds the G7 Presidency, committed the first $50 million in funding toward the new initiative.

“Pandemics pose some of the biggest threats in the world to people’s lives and to economies, and for the first time we will have a system that can move funding and teams of experts to the sites of outbreaks before they spin out of control,” said Jim Yong Kim, President of the World Bank Group. “This facility addresses a long, collective failure in dealing with pandemics. The Ebola crisis in Guinea, Liberia and Sierra Leone taught all of us that we must be much more vigilant to outbreaks and respond immediately to save lives and also to protect economic growth.”…

…The new facility will accelerate both global and national responses to future outbreaks with pandemic potential. It was built and designed in collaboration with the World Health Organization and the private sector, introducing a new level of rigor into both the financing and the response.

“Recent years have seen a dramatic resurgence of the threat from emerging and re-emerging infectious diseases,” said Margaret Chan, Director-General of the World Health Organization. “WHO fully supports the Pandemic Emergency Financing Facility as a critical contribution to global health security and a crucial line of defence against high-threat pathogens.”

The PEF includes an insurance window, which combines funding from the reinsurance markets with the proceeds of World Bank-issued pandemic (catastrophe, or Cat) bonds, as well as a complementary cash window. This will be the first time World Bank Cat Bonds have been used to combat infectious diseases. In the event of an outbreak, the PEF will release funds quickly to countries and qualified international responding agencies.

The insurance window will provide coverage up to $500 million for an initial period of three years for outbreaks of infectious diseases most likely to cause major epidemics, including new Orthomyxoviruses (e.g. new influenza pandemic virus A, B and C), Coronaviridae (e.g. SARS, MERS), Filoviridae (e.g. Ebola, Marburg) and other zoonotic diseases (e.g. Crimean Congo, Rift Valley, Lassa fever). Parametric triggers designed with publicly available data will determine when the money would be released, based on the size, severity and spread of the outbreak.

The complementary cash window will provide more flexible funding to address a larger set of emerging pathogens, which may not yet meet the activation criteria for the insurance window.
All 77 countries eligible for financing from the International Development Association, the World Bank Group’s fund for the poorest countries, will be eligible to receive coverage from the PEF. The PEF is expected to be operational later this year…

…Four global expert panels that were convened over the past year in the wake of the Ebola crisis concluded that the world must urgently step up its capacity for a swift response to outbreaks before they become more deadly and costly pandemics.

The PEF will do a number of important things to prevent another Ebola crisis:
:: It will insure the world’s poorest countries against the threat of a pandemic.
:: In the event of a severe infectious disease outbreak, it will release funds quickly to the countries and/or to international responders, to accelerate the response—saving lives and reducing human suffering.
:: By mobilizing an earlier, faster, better planned and coordinated response, it will reduce the costs to countries and their people for response and recovery.
:: It will promote greater global and national investments in preparing for future outbreaks and strengthening national health systems.
:: It will combine public and private resources to advance global health security, and create a new insurance market for managing pandemic risk.

The World Bank Group estimates that if the PEF had existed in mid-2014 as the Ebola outbreak was spreading rapidly in West Africa, it could have mobilized an initial $100 million as early as July to severely limit the spread and severity of the epidemic. Instead, money at that scale did not begin to flow until three months later. During that three month period, the number of Ebola cases increased tenfold. The Ebola epidemic has claimed more than 11,300 lives and cost at least $10 billion to date. International assistance has totaled more than $7 billion for Ebola response and recovery.

European Vaccine Initiative [to 21 May 2016]
http://www.euvaccine.eu/news-events
News
Second Global Vaccine and Immunization Research Forum (GVIRF) from WHO – Presentations now available
17 May 2016
The presentations given at the captioned forum 15 – 17 March 2016 in Johannesburg are now available.

AERAS [to 21 May 2016]
http://www.aeras.org/pressreleases

.
May 20, 2016
Aeras Applauds the Final Report and Recommendations by the United Kingdom Review on Antimicrobial Resistance
Rockville, MD,– Aeras applauds the Final Report and Recommendations released this week by the U.K. Review on Antimicrobial Resistance (Review) that highlights the extreme global health threat of antimicrobial resistance (AMR). The Review led by economist Jim O’Neill, specifically notes the threat of multidrug-resistant TB (MDR-TB) and the imperative of increased global investment in research and development to save the millions of lives lost each year due to AMR related to tuberculosis (TB) and other infectious diseases.

The final report warns that if new therapies, diagnostics and a new vaccine are not introduced, MDR-TB will be responsible for 2.5 million deaths per year by 2050, or roughly one quarter of the forecasted 10 million deaths related to AMR – equating to one death due to MDR-TB every 12 seconds. An interim paper entitled Vaccines and Alternative Approaches: Reducing our Dependence on Antimicobials published by the Review in February 2016 also emphasized the overwhelming need for new TB vaccines as an essential component of the global strategy to overcome TB and to address MDR-TB…

Fondation Merieux [to 21 May 2016]
Mission: Contribute to global health by strengthening local capacities of developing countries to reduce the impact of infectious diseases on vulnerable populations.
http://www.fondation-merieux.org/news
17 May 2016, Ouagadougou (Burkina Faso)
2nd Regional WARDS Workshop on Laboratory Strengthening and Networks in the 15 ECOWAS Countries and RESAOLAB Workshops in Collaboration with WAHO
Some 70 participants, including the leading figures in clinical biology from the 15 ECOWAS countries, are gathering in Ouagadougou in Burkina Faso, May 17-19 for the West African Regional Disease Surveillance (WARDS) project’s 2nd regional workshop on laboratory strengthening and networks and RESAOLAB** technical workshops.

GHIT Fund [to 21 May 2016]
https://www.ghitfund.org/
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical companies, the Japanese Government and the Bill & Melinda Gates Foundation.

.
2016.05.20 Press Room
Government of Japan Announces Decision to Contribute US$130 million to GHIT Fund/UNDP Replenishment
TOKYO, JAPAN (May 20, 2016)—Today, the Government of Japan (GOJ) announced its policy ahead of the G7 Ise-Shima Summit that it will make a US$130 million contribution to the Global Health Innovative Technology Fund (GHIT Fund) /United Nations Development Programme (UNDP) replenishment, signaling Japan’s unwavering support for research and development (R&D) for malaria, tuberculosis, HIV/AIDS and neglected tropical diseases (NTDs) worldwide.

Launched in 2013 as a public and private partnership, the GHIT Fund has built a robust portfolio of drugs, vaccines and diagnostics. The Fund is expanding: it has invested upwards of US$60 million in more than 60 global product development partnerships that leverage Japanese innovation and capacities in pharmaceuticals. In just three years, the GHIT Fund portfolio is expanding with six of its 23 novel screening programs advancing into next stage of development; two candidates successfully achieving first-in-human trials and an innovative antimalarial drug recently achieving Proof of Concept (Phase II). GHIT is on the ground, having already initiated seven clinical trials for novel candidates in high-burden countries.

The GOJ announcement today will not only allow this innovative work to continue, but will enable GHIT to expand its global development partnerships and its reach around the world. On the health agenda of this year’s G7 Summit in Japan are antimicrobial resistance (AMR) and R&D for infectious disease such as NTDs. Aligned with these goals, GHIT drives forward product development of new technologies to eliminate NTDs and, with over half of its investments targeting resistance in malaria and tuberculosis, is also committed to the fight against AMR.

“Since our initial commitment three years ago, GHIT has made incredible progress in leveraging Japan’s vast cutting-edge science and technology know-how for game-changing tools that have the potential to one day save millions of lives across the globe,” said Dr. Eiji Hinoshita, Director, Global Health Policy Division, International Cooperation Bureau, Ministry of Foreign Affairs. “With today’s announcement, we are incredibly proud to be able to support the continued advancement of these innovations, which, with their rapid advancement through the pipeline, are already poised to make real our vision of a healthier world.”…

Global Fund [to 21 May 2016]
http://www.theglobalfund.org/

.
20 May 2016
Japan Increases Commitment to the Global Fund
TOKYO – The Government of Japan announced today a pledge of US$800 million to the Global Fund to Fight AIDS, Tuberculosis and Malaria for the Fifth Replenishment that starts in 2017, representing a 46 percent increase when measured in Japanese yen, due to fluctuating exchange rates…

.
19 May 2016
Global Fund Strongly Supports Inclusion and Full Participation at High-Level Meeting on Ending AIDS
GENEVA – The Global Fund strongly supports the UNAIDS call for inclusion and full participation of civil society organizations at the 2016 United Nations General Assembly High-Level Meeting on Ending AIDS.

From June 8-10, 2016, world leaders, government representatives, HIV program implementers and civil society organizations from around the world will gather at the United Nations Headquarters in New York to develop a way forward to reach the Sustainable Development Goal of ending AIDS as an epidemic by 2030.

The voices and perspectives of individuals and nongovernmental organizations working to ensure no one is left behind in the fight against HIV are a crucial part of this important forum, particularly people living with HIV and people most affected by the epidemic, including women and girls, sex workers, people who use drugs, men who have sex with men, and transgender people.

As a 21st-century partnership of governments, civil society, the private sector and people affected by AIDS, TB and malaria, the Global Fund recognizes that ending AIDS as an epidemic can only be achieved with the meaningful engagement and participation of people living with and affected by the disease. Reaching Millennium Development Goal 6 of halting and reversing the AIDS epidemic and the historic milestone of 15 million people on treatment by 2015 were due to a coordinated, committed effort of partners worldwide – including civil society groups.
The High-Level Meeting on Ending AIDS should be guided by the principles on which the successes of the AIDS response are built – inclusion, participation and dignity.

PATH [to 21 May 2016]
http://www.path.org/news/index.php
Press release | May 17, 2016
PATH and Laerdal Global Health to accelerate global access to an innovative feeding cup for preterm and high-risk newborns
The new feeding cup delivers lifesaving nutrients to newborns in low-resource settings who have difficulty breastfeeding

.

Press release | May 17, 2016
PATH in collaboration with Novartis Foundation announce innovative program to tackle hypertension in Vietnam
Communities for Healthy Hearts will improve hypertension screening and management with a focus on empowering patients and health care workers

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

  If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Annals of Internal Medicine
17 May 2016, Vol. 164. No. 10
http://annals.org/issue.aspx
Ideas and Opinions
Emergence of Congenital Zika Syndrome: Viewpoint From the Front Lines FREE
Federico Costa, PhD; Manoel Sarno, MD, PhD; Ricardo Khouri, PhD; Bruno de Paula Freitas, MD; Isadora Siqueira, MD, PhD; Guilherme S. Ribeiro, MD, PhD; Hugo C. Ribeiro, MD; Gubio S. Campos, PhD; Luiz C. Alcântara, PhD; Mitermayer G. Reis, MD, PhD; Scott C. Weaver, PhD; Nikos Vasilakis, PhD; Albert I. Ko, MD; and Antonio Raimundo Almeida, MD, PhD
[No abstract; Final text]
…Although recent advances in flavivirus vaccines may guide relatively rapid development of a Zika vaccine, availability is still probably years away. Treatment with a monoclonal antibody could also be developed quickly on the basis of promising past results with flaviviruses. However, systematic investigations of pregnant women and newborns will still be needed to determine the risk for transplacental infection and development of severe congenital sequelae that can, in turn, guide effective diagnostic and prevention efforts.

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 21 May 2016)

.
Research article
Improving the uptake of pre-travel health advice amongst migrant Australians: exploring the attitudes of primary care providers and migrant community groups
Migrant travellers who return to their country of origin to visit family and friends (VFR) are less likely to seek travel-related medical care and are less likely to adhere to recommended medications …
Holly Seale, Rajneesh Kaur, Abela Mahimbo, C. Raina MacIntyre, Nicholas Zwar, Mitchell Smith, Heather Worth and Anita E Heywood
BMC Infectious Diseases 2016 16:213
Published on: 18 May 2016

.

Research article
Initiation and completion rates for latent tuberculosis infection treatment: a systematic review
Control of latent tuberculosis infection (LTBI) is an important step towards tuberculosis elimination. Preventive treatment will prevent the development of disease in most cases diagnosed with LTBI.
Andreas Sandgren, Marije Vonk Noordegraaf-Schouten, Femke van Kessel, Anke Stuurman, Anouk Oordt-Speets and Marieke J. van der Werf
BMC Infectious Diseases 2016 16:204
Published on: 17 May 2016

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 21 May 2016)

.
Research article
Human newborn bacille Calmette–Guérin vaccination and risk of tuberculosis disease: a case-control study
Helen A. Fletcher, Ali Filali-Mouhim, Elisa Nemes, Anthony Hawkridge, Alana Keyser, Samuel Njikan, Mark Hatherill, Thomas J. Scriba, Brian Abel, Benjamin M. Kagina, Ashley Veldsman, Nancy Marín Agudelo, Gilla Kaplan, Gregory D. Hussey, Rafick-Pierre Sekaly and Willem A. Hanekom
Published on: 16 May 201
Abstract
Background
An incomplete understanding of the immunological mechanisms underlying protection against tuberculosis (TB) hampers the development of new vaccines against TB. We aimed to define host correlates of prospective risk of TB disease following bacille Calmette–Guérin (BCG) vaccination.
Methods
In this study, 5,726 infants vaccinated with BCG at birth were enrolled. Host responses in blood collected at 10 weeks of age were compared between infants who developed pulmonary TB disease during 2 years of follow-up (cases) and those who remained healthy (controls).
Results
Comprehensive gene expression and cellular and soluble marker analysis failed to identify a correlate of risk. We showed that distinct host responses after BCG vaccination may be the reason: two major clusters of gene expression, with different myeloid and lymphoid activation and inflammatory patterns, were evident when all infants were examined together. Cases from each cluster demonstrated distinct patterns of gene expression, which were confirmed by cellular assays.
Conclusions
Distinct patterns of host responses to Mycobacterium bovis BCG suggest that novel TB vaccines may also elicit distinct patterns of host responses. This diversity should be considered in future TB vaccine development.

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 21 May 2016)

.
Research article
How equitable are community health worker programmes and which programme features influence equity of community health worker services? A systematic review
Community health workers (CHWs) are uniquely placed to link communities with the health system, playing a role in improving the reach of health systems and bringing health services closer to hard-to-reach and …
Rosalind McCollum, Woedem Gomez, Sally Theobald and Miriam Taegtmeyer
BMC Public Health 2016 16:419
Published on: 20 May 2016

Research article
Using short-message-service notification as a method to improve acute flaccid paralysis surveillance in Papua New Guinea
High quality acute flaccid paralysis (AFP) surveillance is required to maintain polio-free status of a country. Papua New Guinea (PNG) is considered as one of the highest risk countries for polio re-importation…
Siddhartha Sankar Datta, Berry Ropa, Gerard Pai Sui, Ramzi Khattar, Ravi Shankar Santhana Gopala Krishnan and Hiromasa Okayasu
BMC Public Health 2016 16:409
Published on: 17 May 2016

Debate
Critiquing the response to the Ebola epidemic through a Primary Health Care Approach
The 2014/2015 West Africa Ebola epidemic has caused the global public health community to engage in difficult self-reflection.
Vera Scott, Sarah Crawford-Browne and David Sanders
BMC Public Health 2016 16:410
Published on: 17 May 2016

Research article
Associations in the continuum of care for maternal, newborn and child health: a population-based study of 12 sub-Saharan Africa countries
Despite the progress in the Millennium Development Goals (MDGs) 4 and 5, inequity in the utilization of maternal, newborn and child health (MNCH) care services still remain high in sub-Saharan Africa (SSA).
Patrick Opiyo Owili, Miriam Adoyo Muga, Yiing-Jenq Chou, Yi-Hsin Elsa Hsu, Nicole Huang and Li-Yin Chien
BMC Public Health 2016 16:414
Published on: 17 May 2016

British Medical Journal
21 May 2016 (vol 352, issue 8058)
http://www.bmj.com/content/353/8058

.
Research Update
Deaths, late deaths, and role of infecting dose in Ebola virus disease in Sierra Leone: retrospective cohort study
BMJ 2016; 353 :i2403 (Published 17 May 2016)
Abstract
Objectives To assess the frequency of fatal recrudescence from Ebola virus disease after discharge from treatment centres, and explore the influence of infecting dose on case fatality rates.
Design Retrospective cohort study.
Setting Western Area, Sierra Leone.
Participants 151 survivors treated for Ebola virus disease at the Kerry Town treatment centre and discharged. Survivors were followed up for a vital status check at four to nine months after discharge, and again at six to 13 months after discharge. Verbal autopsies were conducted for four survivors who had died since discharge (that is, late deaths). Survivors still living in Western Area were interviewed together with their household members. Exposure level to Ebola virus disease was ascertained as a proxy of infecting dose, including for those who died.
Main outcome measures Risks and causes of late death; case fatality rates; odds ratios of death from Ebola virus disease by age, sex, exposure level, date, occupation, and household risk factors.
Results Follow-up information was obtained on all 151 survivors of Ebola virus disease, a mean of 10 months after discharge. Four deaths occurred after discharge, all within six weeks: two probably due to late complications, one to prior tuberculosis, and only one after apparent full recovery, giving a maximum estimate of recrudescence leading to death of 0.7%. In these households, 395 people were reported to have had Ebola virus disease, of whom 227 died. A further 53 people fulfilled the case definition for probable disease, of whom 11 died. Therefore, the case fatality rate was 57.5% (227/395) for reported Ebola virus disease, or 53.1% (238/448) including probable disease. Case fatality rates were higher in children aged under 2 years and adults older than 30 years, in larger households, and in infections occurring earlier in the epidemic in Sierra Leone. There was no consistent trend of case fatality rate with exposure level, although increasing exposure increased the risk of Ebola virus disease.
Conclusions In this study of survivors in Western Area, Sierra Leone, late recrudescence of severe Ebola virus disease appears to be rare. There was no evidence for an effect of infecting dose (as measured by exposure level) on the severity of disease.

Clinical Therapeutics
May 2016 Volume 38, Issue 5, p991-1258
http://www.clinicaltherapeutics.com/current

.
Original Research
Progress Report on Neglected Tropical Disease Drug Donation Programs
Joshua P. Cohen, Lisseth Silva, Alisa Cohen, Josephine Awatin, Robert Sturgeon
p1193–1204
Published online: March 31 2016
Abstract
Purpose
Neglected tropical diseases (NTDs) impose a significant burden on public health, particularly in developing nations. Many can be treated cost-effectively with drugs donated or offered at or below marginal cost. In 2012, the World Health Organization published an NTD roadmap that outlined a strategy for the prevention, control, and eradication of 17 NTDs by 2020. Inspired by this roadmap, executives from 13 pharmaceutical companies, government agencies, and other interested parties signed the London Declaration on Neglected Tropical Diseases in January 2012. In this paper, we will assess progress in meeting commitments on drug donations laid out in the London Declaration.
Methods
We conducted Medline and LexisNexis searches of peer-reviewed publications and trade journals, as well as product development partnership and government reports. Subsequently, we designed a survey instrument and surveyed 10 company signatories (companies with drug donation programs) to the London Declaration to determine current donations and pledges.
Findings
Nine of 10 companies with donation programs responded to the survey. The respondents reported substantial progress in meeting the goals laid out in the London Declaration. Survey respondents maintained 17 drug donation programs across 10 disease categories. In 2014, companies donated >1 billion treatments, with a dollar value of nearly $1.5 billion. However, not all donated products were distributed to patients in need. In addition, 4 of the 17 programs were slated to end before 2020, three of the 17 programs did not report explicit program objectives, and 7 of 17 did not measure the impact of programs in terms of numbers of patients treated. None of our survey respondents reported on whether the programs were leading to a reduction in disease prevalence.
Implications
Donations are a necessary but insufficient condition for patient access to neglected disease drugs. Additional resources must be allocated to ensure delivery of donated products to patients. In addition, drug donation programs should provide explicit descriptions of program objectives, measurements of the impacts of their programs, and extension of all donation commitments through 2020. To achieve this, multiple stakeholders with a vested interest in reducing the burden of neglected diseases must collaborate in a multipronged approach toward NTD elimination.

Development in Practice
Volume 26, Issue 4, 2016
http://www.tandfonline.com/toc/cdip20/current

.

Articles
NGO–researcher partnerships in global health research: benefits, challenges, and approaches that promote success
DOI:10.1080/09614524.2016.1164122
Catherine Olivier, Matthew R. Hunt & Valéry Ridde
pages 444-455
Open access
Published online: 13 Apr 2016
ABSTRACT
Partnerships involving NGOs and academic researchers (NGO–R partnerships) are increasing in global health research. Such collaborations present opportunities for knowledge translation in global health, yet are also associated with challenges for establishing and sustaining effective and respectful partnerships. We conducted a narrative review of the literature to identify benefits and challenges associated with NGO–R partnerships, as well as approaches that promote successful partnerships. We illustrate this analysis with examples from our own experiences. The results suggest that collaborations characterised by trust, transparency, respect, solidarity, and mutuality contribute to the development of successful and sustainable NGO–R partnerships.

Eurosurveillance
Volume 21, Issue 20, 19 May 2016
http://www.eurosurveillance.org/Public/Articles/Archives.aspx?PublicationId=11678

.
Rapid communications
Outbreak of a new measles B3 variant in the Roma/Sinti population with transmission in the nosocomial setting, Italy, November 2015 to April 2016
by A Filia, A Amendola, M Faccini, M Del Manso, S Senatore, S Bianchi, BM Borrini, A Ciampelli, E Tanzi, MT Filipponi, G Piccirilli, T Lazzarotto, MG Pascucci, M Baggieri, F Magurano

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 21 May 2016]

.
Research
Global health partnerships: building multi-national collaborations to achieve lasting improvements in maternal and neonatal health
In response to health care challenges worldwide, extensive funding has been channeled to the world’s most vulnerable health systems. Funding alone is not sufficient to address the complex issues and challenges…
Rohit Ramaswamy, Brianne Kallam, Dragica Kopic, Borislava Pujic and Medge D. Owen
Globalization and Health 2016 12:22
Published on: 20 May 2016

.
Research
Discourse, ideas and power in global health policy networks: political attention for maternal and child health in the millennium development goal era
Maternal and child health issues have gained global political attention and resources in the past 10 years, due in part to their prominence on the Millennium Development Goal agenda and the use of evidence-based…
Lori McDougall
Globalization and Health 2016 12:21
Published on: 18 May 2016

.
Research
From local to global: a qualitative review of the multi-leveled impact of a multi-country health research capacity development partnership on maternal health in Sudan
There is a substantial body of literature on the principles of good partnerships and the rationale for such partnerships in research capacity strengthening. This paper illustrates the long term effects…
Khalifa Elmusharaf, Hanan Tahir, Diarmuid O’ Donovan, Ruairi Brugha, Mamoun Homeida, Amal M. O. Abbas and Elaine Byrne
Globalization and Health 2016 12:20
Published on: 16 May 2016

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 21 May 2016]

.
Research
Which health research gets used and why? An empirical analysis of 30 cases
Maarten Olivier Kok, John Owusu Gyapong, Ivan Wolffers, David Ofori-Adjei and Joost Ruitenberg
Published on: 17 May 2016
Abstract
Background
While health research is considered essential for improving health worldwide, it remains unclear how it is best organized to contribute to health. This study examined research that was part of a Ghanaian-Dutch research program that aimed to increase the likelihood that results would be used by funding research that focused on national research priorities and was led by local researchers. The aim of this study was to map the contribution of this research to action and examine which features of research and translation processes were associated with the use of the results.
Methods
Using Contribution Mapping, we systematically examined how 30 studies evolved and how results were used to contribute to action. We combined interviews with 113 purposively selected key informants, document analysis and triangulation to map how research and translation processes evolved and contributions to action were realized. After each case was analysed separately, a cross-case analysis was conducted to identify patterns in the association between features of research processes and the use of research.
Results
The results of 20 of the 30 studies were used to contribute to action within 12 months. The priority setting and proposal selection process led to the funding of studies which were from the outset closely aligned with health sector priorities. Research was most likely to be used when it was initiated and conducted by people who were in a position to use their results in their own work. The results of 17 out of 18 of these user-initiated studies were translated into action. Other features of research that appeared to contribute to its use were involving potential key users in formulating proposals and developing recommendations.
Conclusions
Our study underlines the importance of supporting research that meets locally-expressed needs and that is led by people embedded in the contexts in which results can be used. Supporting the involvement of health sector professionals in the design, conduct and interpretation of research appears to be an especially worthwhile investment.